Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark surveyRuben A. Mesa, John Mascarenhas, Carole B. Miller et al.|BMC Cancer|2016Cited by 194
Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval SummaryKatherine A. Thornton, Richard Pazdur, Geoffrey Kim et al.|Clinical Cancer Research|2012Cited by 149
Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark surveyRuben A. Mesa, John Mascarenhas, Sara Goldberger et al.|Cancer|2016Cited by 91
Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United StatesRuben A. Mesa, John Mascarenhas, Carole B. Miller et al.|Blood|2014Cited by 14
Gaps in Perception Between Patients and Physicians Regarding Symptomatology and Treatment Attitudes for Myeloproliferative Neoplasms: MPN LANDMARK SURVEYRuben A. Mesa, John Mascarenhas, Carole B. Miller et al.|Blood|2014Cited by 2